PetVivo to exhibit at TEVA summer symposium in Texas

PetVivo Holdings will showcase its veterinary products at the Texas Equine Veterinary Association’s 2026 Summer CE Symposium from July 30 to Aug. 1 at Horseshoe Bay Resort in Texas. The appearance puts SPRYNG and PrecisePRP in front of equine veterinarians as the company works to expand awareness and commercial adoption.

Why it matters: - The TEVA symposium gives PetVivo direct access to equine veterinarians who treat joint pain, lameness and soft tissue injuries in horses. - The event could help PetVivo build awareness for SPRYNG with OsteoCushion Technology and PrecisePRP among practitioners who influence treatment decisions. - PetVivo is using the symposium to push broader adoption of veterinary regenerative and joint-care products.

What happened: - PetVivo Holdings said it will exhibit at the Texas Equine Veterinary Association 2026 Summer CE Symposium. - The symposium runs July 30-Aug. 1, 2026, at Horseshoe Bay Resort in Horseshoe Bay, Texas. - PetVivo will be at booth/table 78 during the event. - Exhibit hours are Thursday, July 30 from 2:30 p.m. to 8:00 p.m., Friday, July 31 from 10:00 a.m. to 4:00 p.m., and Saturday, Aug. 1 from 10:00 a.m. to 1:30 p.m.

The details: - PetVivo plans to feature SPRYNG with OsteoCushion Technology, an intra-articular injectable veterinary medical device made of sterilized extracellular matrix microparticles. - After injection, the microparticles adsorb to the synovial lining and integrate with subsynovial tissue. - The product is designed to support restoration of normal joint mechanics. - SPRYNG is intended to assist in managing noninfectious sources of joint pain, including osteoarthritis, degenerative joint disease and joint instability. - PetVivo also referenced PrecisePRP in connection with the symposium. - CEO John Lai said the symposium brings together respected equine veterinarians and offers a chance to discuss clinical evidence supporting the company’s products. - PetVivo told interested parties to contact info1@petvivo.com or visit more information, PetVivo Animal Health and SPRYNG Health. - The company operates with subsidiaries PetVivo Animal Health, Cosmeta Corp. and PetVivo AI, Inc. - PetVivo describes itself as an emerging biomedical device company focused on manufacturing, commercialization and licensing of medical devices and therapeutics for companion animals. - PetVivo says its strategy is to adapt human therapies for animals in a capital- and time-efficient way. - The company says veterinary medical devices can reach market earlier than more stringently regulated pharmaceuticals and biologics. - PetVivo says it has a pipeline of products for animals and people. - The company says its intellectual property portfolio includes 12 patents and six trade secrets. - PetVivo says SPRYNG is a veterinarian-administered intra-articular injection for managing lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs and horses. - PetVivo says PrecisePRP is an off-the-shelf platelet-rich plasma product for veterinarians. - Both SPRYNG and PrecisePRP are available for commercial sale.

Between the lines: - The symposium appearance signals PetVivo’s focus on meeting buyers and influencers in a concentrated veterinary setting rather than relying only on broad consumer outreach. - The company is pairing product demos with messaging about clinical evidence, which suggests it is still working to convert awareness into adoption. - PetVivo’s repeated emphasis on faster commercialization for veterinary devices points to a strategy built around speed to market and lower regulatory friction.

What's next: - PetVivo is likely to use the TEVA event to generate practitioner interest and follow up on product conversations after the symposium. - The company may continue promoting SPRYNG and PrecisePRP at veterinary conferences as part of a broader commercial rollout. - PetVivo noted that risks to its business are detailed in its Annual Report on Form 10-K for the year ended March 31, 2026, and other SEC filings. - The company also included a standard forward-looking statement disclaimer, saying future plans and results are subject to risks and uncertainties.

The bottom line: - PetVivo is taking its veterinary sales push directly to equine specialists in Texas, with product visibility and clinical positioning at the center of the effort.